EMA starts rolling review for Eli Lilly's Covid-19 treatment

Two new antibodies for Covid-19 have been placed under rolling review by the EMA. This will ensure faster approval in case the drug reaches the point of submitting an application.
Photo: MIKE SEGAR/REUTERS / X90033
Photo: MIKE SEGAR/REUTERS / X90033
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

The European Medicines Agency (EMA) has started reviewing the preliminary data on two Eli Lilly treatments for Covid-19, writes the Danish Medicines Agency in a press announcement.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading